Simulations Plus Inc. on Thursday announced the launch of its version 1.0 PKPlus software, which is used to analyze preclinical and clinical trial data. The Lancaster company provides software and consulting services for pharmaceutical research and spent over two years developing PKPlus, which has been a component of the company’s GastroPlus software system since 2000. PKPlus was redeveloped as a standalone product that incorporates relational database Microsoft SQL Server Express, generates automatic and custom reports as well as provides a full audit trail and validation for U.S. Food and Drug Administration submission. “PKPlus combines sophistication and simplicity, providing the capabilities to meet the needs of scientists across departments at pharmaceutical companies, contract research organizations and other non-pharma markets,” John DiBella, vice president of marketing and sales at Simulations Plus, said in a statement. “With the value pricing and flexible licensing policies we have implemented, we believe it has the potential to become a significant contributor to revenues and earnings going forward,” Simulations Plus shares closed up 7 cents, or nearly 1 percent, to $8.12 on the Nasdaq.
